Corgentech Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $124M

Corgentech General Information

Description

Provider of biopharmaceutical products and services based in San Francisco, California. The company is engaged in discovery, development and commercialization of a new class of therapeutics called transcription factor decoys.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 650 Gateway Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Human Capital Services
Acquirer
Anesiva
Corporate Office
  • 650 Gateway Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Corgentech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 26-Sep-2005 $124M Completed Profitable
7. PIPE Completed Profitable
6. IPO 12-Feb-2004 Completed Profitable
5. Later Stage VC (Series D) 20-Oct-2003 Completed Profitable
4. Later Stage VC 17-Oct-2003 Completed Profitable
3. Later Stage VC (Series D) 10-Oct-2002 Completed Product Development
2. Early Stage VC (Series B) 01-May-2001 $13M $15.5M Completed Product Development
1. Early Stage VC (Series A) 01-Feb-1999 $2.5M $2.5M Completed Product Development
To view Corgentech’s complete valuation and funding history, request access »

Corgentech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B1
Series B 10,000,000 $0.001000 8% $1 $1 1x $1 12.65%
Series A 4,325,254 $0.001000 8% $0.58 $0.58 1x $0.58 5.47%
To view Corgentech’s complete cap table history, request access »

Corgentech Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alta Partners Venture Capital Minority
Axiom Venture Partners Venture Capital Minority
Bear Stearns Health InnoVentures Management Venture Capital Minority
Bristol-Myers Squibb Corporation Minority
CCMP Capital Advisors PE/Buyout Minority
You’re viewing 5 of 16 investors. Get the full list »

Corgentech Acquisitions (1)

Corgentech’s most recent deal was a Reverse Merger with Anesiva. The deal was made on 26-Sep-2005.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Anesiva 26-Sep-2005 Reverse Merger Drug Discovery
To view Corgentech’s complete acquisitions history, request access »

Corgentech FAQs

  • When was Corgentech founded?

    Corgentech was founded in 1999.

  • Where is Corgentech headquartered?

    Corgentech is headquartered in South San Francisco, CA.

  • What industry is Corgentech in?

    Corgentech’s primary industry is Biotechnology.

  • Is Corgentech a private or public company?

    Corgentech is a Private company.

  • What is the current valuation of Corgentech?

    The current valuation of Corgentech is .

  • What is Corgentech’s current revenue?

    The current revenue for Corgentech is .

  • How much funding has Corgentech raised over time?

    Corgentech has raised $216M.

  • Who are Corgentech’s investors?

    Alta Partners, Axiom Venture Partners, Bear Stearns Health InnoVentures Management, Bristol-Myers Squibb, and CCMP Capital Advisors are 5 of 16 investors who have invested in Corgentech.

  • When was Corgentech acquired?

    Corgentech was acquired on 26-Sep-2005.

  • Who acquired Corgentech?

    Corgentech was acquired by Anesiva.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process